$2 Billion for Quantum—But Was It Legal to Spend?

The checks went out. Then came the lawyers.

Last week, the US government announced $2 billion in investments across a slate of quantum computing startups—$100 million apiece, in exchange for equity stakes. For companies burning cash in a field where commercial viability is still years away, that kind of backing can be the difference between survival and shutdown. The announcement was celebrated. Then, within days, a senior member of Congress called it illegal.

Zoe Lofgren (D–Calif.), ranking member of the House Science, Space, and Technology Committee, made her position clear: the money wasn't Congress's to spend this way. The funds had been appropriated for public semiconductor research—not for the government to become a venture capitalist in quantum hardware.

The Company That Wouldn't Exist Without This Deal

The centerpiece of the announcement is a company called Anderon, and it's where the legal and strategic stakes converge most sharply. Anderon doesn't have a long history or an independent founding story. It is, essentially, a creation of this policy decision.

The structure: IBM and the federal government each put in $1 billion. Anderon inherits personnel and intellectual property from IBM, and it will operate as a foundry—fabricating quantum processing units (QPUs) and contracting those services out to IBM and any other company willing to pay for access to cutting-edge quantum hardware. Think of it as a TSMC model, applied to quantum chips.

The ambition is real. A dedicated QPU foundry could accelerate the entire quantum ecosystem by giving companies access to advanced hardware without having to build fabrication infrastructure themselves. But the fact that this company's existence depends entirely on a funding decision whose legal basis is now contested makes its future genuinely uncertain.

Sponsored

Advertise with Us

[email protected]

Sponsored

The Constitutional Fault Line

Lofgren's objection isn't about whether quantum computing deserves investment. It's about who gets to decide how public money is spent—and on what.

Under the US Constitution, Congress holds the power of the purse. When lawmakers appropriated funds for semiconductor public research, they were authorizing a specific use. The administration's decision to redirect that money toward equity stakes in private companies—essentially acting as a government venture fund—may constitute an unauthorized reprogramming of appropriated funds. Legal scholars are divided on where exactly the line falls, but the concern is structurally serious.

The timing reveals the underlying tension. With China pouring state resources into quantum computing, the administration clearly felt that waiting for a new congressional authorization cycle would cost the US ground it couldn't afford to lose. Speed versus process. That's a familiar argument in technology policy—and it rarely resolves cleanly.

Who Wins, Who Worries

For the startups receiving $100 million each, the immediate reaction is relief. Quantum computing companies routinely operate for a decade before generating meaningful revenue. Government backing at this scale extends runways, attracts private co-investors, and signals national commitment to the sector. If the legal challenge succeeds and funding is clawed back or frozen, some of these companies may not survive the gap.

IBM's calculus is different. The company gets a government-funded partner to absorb the capital-intensive work of QPU fabrication while retaining access to the output. It's a structure that offloads financial risk while preserving strategic advantage. Critics might call it a sweetheart deal; supporters would call it smart industrial policy.

For Congress, the issue transcends quantum computing. If the administration can redirect appropriated funds toward equity investments in emerging technology sectors without explicit authorization, the precedent extends well beyond this case. The next administration—of either party—could apply the same logic to AI, biotech, or energy.